Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Instil Bio, Inc. (TIL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $7.23, with a market capitalisation of $50.53M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.67 to $25.55. This page covers its latest market performance, valuation, price trends and company information.
$50.53M | |
$7.46 | |
$589.80 | |
$5.67 | |
$7.45 | |
17.13K | |
12.25K | |
-- | |
$25.55 | |
$5.67 | |
-- | |
-- |
Instil Bio, Inc. (TIL) is trading at $7.40 in pre-market trading as of 2026-09-15 23:31:00, down 0.66% ($0.05) from the previous close of $7.45
Pre-market trading shows how investors are pricing TIL before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Instil Bio, Inc. (TIL) moved from $7.58 to $7.23, representing a decline of 4.68% ($0.36).
The stock traded between $7.18 and $7.82 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 14.61 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 7.8%
TIL is currently trading at $7.23, placing it 7.8% of the way from its 52-week low of $5.67 to its 52-week high of $25.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Instil Bio, Inc. (TIL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.